MYGN
Myriad Genetics Inc
Price:  
23.99 
USD
Volume:  
680,508.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

MYGN EV/EBITDA

-129.5%
Upside

As of 2024-05-23, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -37.52. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 2,112.42 mil USD. MYGN's TTM EBITDA according to its financial statements is -56.30 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 9.4x - 13.4x 11.2x
Forward P/E multiples 10.1x - 19.3x 13.6x
Fair Price (5.67) - (7.68) (7.07)
Upside -123.6% - -132.0% -129.5%
23.99 USD
Stock Price
(7.07) USD
Fair Price

MYGN EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-05-22 -37.52
2024-05-21 -38.15
2024-05-20 -39.16
2024-05-17 -39.61
2024-05-16 -38.52
2024-05-15 -38.60
2024-05-14 -39.72
2024-05-13 -39.03
2024-05-10 -39.90
2024-05-09 -39.55
2024-05-08 -37.46
2024-05-07 -30.75
2024-05-06 -31.06
2024-05-03 -30.26
2024-05-02 -29.85
2024-05-01 -30.26
2024-04-30 -30.42
2024-04-29 -30.79
2024-04-26 -28.18
2024-04-25 -27.86
2024-04-24 -28.91
2024-04-23 -28.86
2024-04-22 -28.68
2024-04-19 -28.70
2024-04-18 -28.71
2024-04-17 -28.92
2024-04-16 -29.37
2024-04-15 -29.77
2024-04-12 -30.39
2024-04-11 -31.91
2024-04-10 -31.53
2024-04-09 -32.52
2024-04-08 -31.65
2024-04-05 -31.53
2024-04-04 -31.46
2024-04-03 -31.59
2024-04-02 -31.11
2024-04-01 -33.42
2024-03-28 -33.23
2024-03-27 -33.36
2024-03-26 -33.50
2024-03-25 -34.29
2024-03-22 -34.71
2024-03-21 -34.80
2024-03-20 -34.71
2024-03-19 -33.68
2024-03-18 -33.73
2024-03-15 -32.97
2024-03-14 -33.23
2024-03-13 -33.57